Dr. DiBianco describes alpha validation phase of surgical decision aid for stone treatment

Video

“We thought anesthesia type would be relevant. But both urologists and patients determined that it actually was not relevant to their decision making,” says John Michael DiBianco, MD.

In this video, John Michael DiBianco, MD, discusses the next steps for a surgical decision aid evaluated in the recent Journal of Endourology paper, “Development of a Surgical Decision Aid for Patients with Nephrolithiasis: Shockwave Lithotripsy vs Ureteroscopy.” DiBianco is an assistant professor of urology at the University of Florida, Gainesville.

Transcript:

The actual beginning, what we call the alpha validation, was interesting in the fact that we thought anesthesia type would be relevant. But both urologists and patients determined that it actually was not relevant to their decision making. So that one had to be removed in the first phase of the validation. Patient advocates also scored that recovery time was not 100% relevant, although physicians and urologists did, so we kept that one in there. It's certainly not ready for primetime or anything like that. We've done the alpha validation. And so now we have to work on the broader validation, where we have a more diverse group of physicians, a more diverse group of patients looking at it and using it, and then using some targeted groups to study some objective measures of how well it did what it was intended to do. And so hopefully, we'll get started on some of those randomized trials in the future.

This transcript was edited for clarity.

Related Videos
Dr. Jordan Allen in an interview with Urology Times
Human kidney cross section on science background | Image Credit: © Crystal light - stock.adobe.com
Illustration of kidney stones | Image Credit: © freshidea - stock.adobe.com
Smita De, MD, PhD, answers a question during a Zoom video interview
Smita De, MD, PhD, answers a question during a Zoom video interview
Close-up of elderly woman about to take aspirin | Image Credit: ©  fizkes - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.